Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...

Meek has held the top job at Mirati since 2021, overseeing the company as it successfully brought KRAS inhibitor Krazati (adagrasib) to market in the US as a second-line treatment for non-small ...

Mirati Therapeutics Inc., a Bristol Myers Squibb company, funded this study. Last week, Bristol Myers announced results from the Phase 3 KRYSTAL-12 study, evaluating Krazati (adagrasib ...

We remind the investors that Krazati was added to Bristol Myers’ oncology portfolio following the $4.8 billion acquisition of Mirati Therapeutics, which was completed in January 2024.

Krazati and Erbitux show significant efficacy in KRAS G12C-mutant mCRC, with ORR of 34% (BICR) and 43% (investigator review). The disease control rate was 85% (BICR) and 86% (investigator review), ...